Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (421-430 of 578) with videos related to

Pageof 58
Sort By:
Breast Cancer Research and Treatment|July 17, 2008
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptorsOlivier Brouckaert, Saskia Pintens, Vanya Van Belle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire StudyEric Pujade-Lauraine, Frédéric Selle, Béatrice Weber, et al.
JCO Precision Oncology|January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 TrialEric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
Nature Cell Biology|August 3, 2019
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screeningMatteo Boretto, Nina Maenhoudt, Xinlong Luo, et al.
Cell Research|June 21, 2020
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profilingJunbin Qian, Siel Olbrecht, Bram Boeckx, et al.
The New England Journal of Medicine|September 8, 2010
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerIgnace Vergote, Claes G Tropé, Frédéric Amant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Sentinel node dissection is safe in the treatment of early-stage vulvar cancerAte G J Van der Zee, Maaike H Oonk, Joanne A De Hullu, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Journal of Minimally Invasive Gynecology|September 15, 2019
The LACC Trial and Minimally Invasive Surgery in Cervical CancerIgnace Vergote, Javier F Magrina, Vanna Zanagnolo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 21, 2010
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trialLeen Verleye, Petronella B Ottevanger, Gunnar B Kristensen, et al.
Pageof 58

Showing results (421-430 of 578) with videos related to

Sort By:
Pageof 58
Breast Cancer Research and Treatment|July 17, 2008
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptorsOlivier Brouckaert, Saskia Pintens, Vanya Van Belle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire StudyEric Pujade-Lauraine, Frédéric Selle, Béatrice Weber, et al.
JCO Precision Oncology|January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 TrialEric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
Nature Cell Biology|August 3, 2019
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screeningMatteo Boretto, Nina Maenhoudt, Xinlong Luo, et al.
Cell Research|June 21, 2020
A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profilingJunbin Qian, Siel Olbrecht, Bram Boeckx, et al.
The New England Journal of Medicine|September 8, 2010
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerIgnace Vergote, Claes G Tropé, Frédéric Amant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Sentinel node dissection is safe in the treatment of early-stage vulvar cancerAte G J Van der Zee, Maaike H Oonk, Joanne A De Hullu, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Journal of Minimally Invasive Gynecology|September 15, 2019
The LACC Trial and Minimally Invasive Surgery in Cervical CancerIgnace Vergote, Javier F Magrina, Vanna Zanagnolo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 21, 2010
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trialLeen Verleye, Petronella B Ottevanger, Gunnar B Kristensen, et al.
Pageof 58